Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 1, 2013, Pages 89-93

  Jones, Ronald N ^a,b   Flamm, Robert K ^a   Sader, Helio S ^a   Stilwell, Matthew G ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenems; Ceftaroline; Ceftriaxone; MRSA; Surrogate markers; Susceptibility tests

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; IMIPENEM; MEROPENEM; PENICILLIN G;

AGAR DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENTEROBACTERIACEAE; HAEMOPHILUS INFLUENZAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 84870764909     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.08.022     Document Type: Article

References (20)

1. Barry A.L., Jones R.N. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J Clin Microbiol 1987, 25:1570-1571.
2. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial disk susceptibility tests; approved standard -- 11th edition, M02-A11 2012, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard -- ninth edition, M07-A9 2012, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
5. Corey G.R., Wilcox M., Talbot G.H., Friedland H.D., Baculik T., Witherell G.W., et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010, 51:641-650.
6. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51:1395-1405.
7. Ishikawa T., Matsunaga N., Tawada H., Kuroda N., Nakayama Y., Ishibashi Y., et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003, 11:2427-2437.
8. Jones R.N., Farrell D.J., Mendes R.E., Sader H.S. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: Results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl. 3):iii69-iii80.
9. Jones R.N., Jacobs M.R., Sader H.S. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010, 36:197-204.
10. Jones R.N., Mendes R.E., Sader H.S. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010, 65(Suppl. 4):iv17-iv31.
11. Jones R.N., Pfaller M.A. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-1999). Diagn Microbiol Infect Dis 2001, 39:237-243.
12. Jones R.N., Sader H.S., Fritsche T.R., Hogan P.A., Sheehan D.J. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol 2006, 44:2622-2625.
13. Jones R.N., Sader H.S., Fritsche T.R., Janechek M.J. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis 2007, 59:467-472.
14. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010, 68:334-336.
15. Jones R.N., Zurenko G.E. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagn Microbiol Infect Dis 1993, 17:313-316.
16. Ramirez J.A., Anzueto A.R. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl. 3):iii3-iii9.
17. Sader H.S., Fritsche T.R., Kaniga K., Ge Y., Jones R.N. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005, 49:3501-3512.
18. Teflaro Package Insert 2012. New York City, NY. Accessed June 2012. Available online: http://www.frx.com/pi/Teflaro_pi.pdf.
19. US-FDA Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections Accessed June 2012. Available online:. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm224656.pdf.
20. Zhanel G.G., Sniezek G., Schweizer F., Zelenitsky S., Lagace-Wiens P.R., Rubinstein E., et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 2009, 69:809-831.